Uncategorized

AnCan’s Position on Prostate Cancer Focal Therapy as Primary Treatment: Focal therapy appears to be an appealing option to many men but has important drawbacks. Here’s what guides AnCan Moderators.

Hi-Risk/Recurrent/Advanced PrCa Video Chat, 4/20/26: What to do when assigned control arm in a trial

Hi-Risk/Recurrent/Advanced PrCa Video Chat, 4/14/26: Don’t blame it on the prostate cancer… two Gents report tenderness but is it something else?

Hi-Risk/Recurrent/Advanced PrCa Video Chat, 4/6/26: Dr. Kwon… forever overtreating or undertreating! And… Crestor & Nubeqa don’t mix!

Hi-Risk/Recurrent/Advanced PrCa Video Chat, 3/24/26 – addressing insomnia… and AnCan helps men switch docs

AnCan Keynote at Houston Methodist, Aug 2024 – Can you hear us? Amplifying the patient voice.
How AnCan helps patients make their voice heard.
Rick Davis gives keynote address at Houston Methodist Neal Cancer Center 12th Annual Cancer Symposium. August 2024.

Hi-Risk/Recurrent/Advanced PrCa Video Chat, 3/16/26: Toss up between ANDROMEDA trial and dormant cancer discussion

European Prostate Cancer Virtual Support Group, March 18, 2026: Is 5 years on enzalutamide without a change too long?

Hi-Risk/Recurrent/Advanced PrCa Video Chat, 3/2/26: Two men recur from low levels, one younger, while a much younger man is denovo metastatic

Hi-Risk/Recurrent/Advanced PrCa Video Chat, 3/2/26: AnCan’r considering AMG509 STEAP T-Cell engager; does IDC-P make you high risk?

Learn from AnCan’s Emperors of Estradiol… video chat and discussion – PRICELESS peer discussion about using Estradiol (E2) for prostate cancer management

Hi-Risk/Recurrent/Advanced PrCa Video Chat, 2/24/26: Switching hormone therapy drugs and for how long is the flavor of the day.